-
公开(公告)号：US20180370956A1
公开(公告)日：2018-12-27
申请号：US16009389
申请日：2018-06-15
发明人： Rajeev S. BHIDE , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha Ratna Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Kumar Sistla , Hong Wu
IPC分类号： C07D407/14 , C07D405/14 , C07D405/12 , C07D213/74 , C07D401/14 , C07D417/14 , C07D401/12
摘要： Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
公开(公告)号：US20150284382A1
公开(公告)日：2015-10-08
申请号：US14441705
申请日：2013-11-07
发明人： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC分类号： C07D417/14 , C07D401/14 , C07D405/12 , C07D405/14 , C07D213/74 , C07D401/12
CPC分类号： C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
摘要： Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
摘要翻译： 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是单环杂芳基，且R 1，R 3，R 4，R 5和R 6如本文所定义，可用作激酶调节剂，包括IRAK -4抑制。
-
公开(公告)号：US10023562B2
公开(公告)日：2018-07-17
申请号：US15480682
申请日：2017-04-06
发明人： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC分类号： C07D401/12 , C07D407/14 , C07D405/12 , C07D213/74 , C07D405/14 , C07D401/14 , C07D417/14
摘要： Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
公开(公告)号：US20170210730A1
公开(公告)日：2017-07-27
申请号：US15480682
申请日：2017-04-06
发明人： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC分类号： C07D407/14 , C07D213/74 , C07D417/14 , C07D405/14 , C07D401/14 , C07D405/12 , C07D401/12
CPC分类号： C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
摘要： Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
5.发明授权Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators 有权用作激酶调节剂的双环杂环取代的吡啶基化合物公开(公告)号：US09546153B2
公开(公告)日：2017-01-17
申请号：US14441698
申请日：2013-11-07
发明人： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC分类号： C07D401/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D513/04 , C07D417/14 , C07D471/04
CPC分类号： C07D401/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
摘要： Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.
摘要翻译： 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是双环杂环，并且R 1，R 3，R 4，R 5和R 6如本文所定义，其可用作激酶调节剂，包括IRAK -4调制。
-
公开(公告)号：US09657009B2
公开(公告)日：2017-05-23
申请号：US14441705
申请日：2013-11-07
发明人： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC分类号： C07D213/74 , C07D417/14 , C07D401/14 , C07D401/12 , C07D407/14 , C07D405/12 , C07D405/14
CPC分类号： C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
摘要： Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
7.发明申请BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS 有权双相异构体取代的吡啶化合物有用作激酶调节剂公开(公告)号：US20150274696A1
公开(公告)日：2015-10-01
申请号：US14441698
申请日：2013-11-07
发明人： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC分类号： C07D401/12 , C07D513/04 , C07D471/04 , C07D417/14 , C07D487/04 , C07D417/12 , C07D413/12
CPC分类号： C07D401/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
摘要： Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.
摘要翻译： 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是双环杂环，并且R 1，R 3，R 4，R 5和R 6如本文所定义，其可用作激酶调节剂，包括IRAK -4调制。
-
8.发明申请PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY 审中-公开哌啶衍生物作为化合物受体活性调节剂的产物公开(公告)号：US20130178444A1
公开(公告)日：2013-07-11
申请号：US13785039
申请日：2013-03-05
发明人： John Hynes , Percy H. Carter , Lyndon A.M. Cornelius , T.G. Murali Dhar , John V. Duncia , Satheesh K. Nair , Joseph B. Santella , Jayakumar S. Warrier , Hong Wu
IPC分类号： C07D211/60 , C07F9/59
CPC分类号： C07D211/60 , C07D211/52 , C07F9/59
摘要： The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.
摘要翻译： 本申请描述了式（I）化合物的前药或其立体异构体或其药学上可接受的盐。 此外，公开了使用本发明的前药化合物治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫性病症如类风湿性关节炎的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.026 秒)
